View Financial HealthSwedencare 配当と自社株買い配当金 基準チェック /16Swedencare配当を支払う会社であり、現在の利回りは1.01%です。主要情報1.0%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回り3.6%配当成長4.6%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向91%最近の配当と自社株買いの更新お知らせ • Mar 25Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.2800 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.お知らせ • Feb 13Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.3500 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.すべての更新を表示Recent updatesお知らせ • Apr 23Swedencare AB (Publ) Approves Board ChangesSwedencare AB (publ) at its Annual General Meeting held on April 23, 2026, elected Diego Maurizio and Thomas Thomsen as board members. The Annual General Meeting decided to new elect Thomas Eklund as Chairman of the Board.お知らせ • Mar 26Swedencare Showcases Proden Plaqueoff Crunchy Dental Bites At Global Pet ExpoSwedencare was at Global Pet Expo in Orlando, Florida, from March 25 to 27 in booth #4401 showcasing ProDen PlaqueOff Crunchy Dental Bites. These bite-sized supplements help reduce plaque and tartar buildup while keeping breath fresh, all in a tasty, pet-approved format. Formulated with the brand's signature A.N ProDen (a 100% organic kelp sustainably harvested from pristine Scandinavian waters), these bites offer a simple and tasty way to support a healthier smile. ProDen PlaqueOff is formulated to work naturally without the need for chewing or brushing, supporting the prevention of plaque buildup and the softening of tartar. With no artificial additives, preservatives or flavors, pet parents can confidently give their pets a cleaner, healthier mouth without any unnecessary fillers. These supplements come in a tasty veggie flavor and are available in three convenient sizes: a six-ounce bag for medium and large dogs, a three-ounce bag for small dogs, and a three-ounce bag for cats. Easy to incorporate into any routine, these low-calorie bites can be given daily alongside a pet's regular dental care regimen. Plus, the dog formula is VOHC-approved for both plaque and tartar control, providing pet parents with a trusted, research-backed solution for long-term oral health.お知らせ • Mar 25Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.2800 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.お知らせ • Feb 13Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.3500 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.お知らせ • Dec 10+ 2 more updatesSwedencare AB (publ) to Report Q2, 2026 Results on Jul 22, 2026Swedencare AB (publ) announced that they will report Q2, 2026 results on Jul 22, 2026お知らせ • Nov 09Swedencare AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Apr 02, 2026お知らせ • Oct 31Swedencare AB (publ), Annual General Meeting, Feb 26, 2026Swedencare AB (publ), Annual General Meeting, Feb 26, 2026.お知らせ • May 17Swedencare AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Swedencare AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Apr 24+ 1 more updateSwedencare AB (Publ) Approves Election of Isabelle Guiller as DirectorSwedencare AB (publ) announced that at its AGM held on April 25, 2025, shareholders approved the election of Isabelle Guiller as director.お知らせ • Mar 24Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million.Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million on March 24, 2025. Under the terms of agreement, the initial purchase price is £30 million (approximately SEK 395.4 million) along with a two-year earn-out arrangement. The cash consideration will include £27 million (approximately SEK 355.9 million) drawn from available cash and RCF-credit) and an issue-in-kind of 978,119 shares in Swedencare (approximately SEK 39.5 million) to the seller upon closing, which is expected to take place on April 1, 2025. A condition-based purchase price (earn-out) of a maximum GBP 15 million (SEK 197.7 million) may be paid if certain conditions are met as of April 1, 2027. For the calendar year 2024, Summit Veterinary Pharmaceuticals Limited had revenue of £2.7 million. Post completion of the acquiistion, Summit will continue to be led by Steve Organ, the founder and former owner, for the next two years. Steve will also become a shareholder of Swedencare with 978,119 shares. Advokatfirman Lindahl KB, with the assistance of Reynolds Porter Chamberlain LLP (RPC) acted as legal advisor to Swedencare. Lincoln International acted as exclusive financial advisor to Summit UK for the transaction. Redfern acted as exclusive legal advisor to Summit UK for the transaction. Swedencare AB (publ) (OM:SECARE) completed the acquisition of Summit Veterinary Pharmaceuticals Limited on March 24, 2025.お知らせ • Mar 22Swedencare AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Feb 12, 2026お知らせ • Mar 13Swedencare AB (publ) to Report Fiscal Year 2024 Results on Apr 03, 2025Swedencare AB (publ) announced that they will report fiscal year 2024 results on Apr 03, 2025お知らせ • Jan 22Swedencare AB (publ) to Report Q3, 2025 Results on Oct 22, 2025Swedencare AB (publ) announced that they will report Q3, 2025 results on Oct 22, 2025お知らせ • Nov 20Swedencare AB (publ) to Report Q4, 2024 Results on Mar 11, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results at 9:00 AM, Central European Standard Time on Mar 11, 2025お知らせ • Nov 15Swedencare AB (publ), Annual General Meeting, Apr 24, 2025Swedencare AB (publ), Annual General Meeting, Apr 24, 2025.お知らせ • Aug 23+ 1 more updateSwedencare AB (publ) to Report Q2, 2025 Results on Jul 24, 2025Swedencare AB (publ) announced that they will report Q2, 2025 results on Jul 24, 2025お知らせ • Apr 26+ 2 more updatesSwedencare AB (publ) to Report Q4, 2024 Results on Feb 13, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results on Feb 13, 2025お知らせ • Nov 17Swedencare AB (Publ) Announces Nomination Committee AppointmentsSwedencare AB (publ) appointed a nomination committee for the Annual General Meeting on April 25th, 2024. The Nomination Committee consists of the following persons: Håkan Svanberg, appointed by Håkan Svanberg & Co Health Care AB, Chairman of the Nomination Committee, Heinz-Juergen Bertram, appointed by Symrise AG, Anna Magnusson, appointed by Första AP-fonden.お知らせ • Oct 26+ 3 more updatesSwedencare AB (publ), Annual General Meeting, Apr 25, 2024Swedencare AB (publ), Annual General Meeting, Apr 25, 2024.お知らせ • Jun 07Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billionSymrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion on June 5, 2023. Under the terms, SEK 37.50 per share in cash will be acquired for 111,112,282 shares. The consideration payable in respect of the Offer is financed in full by available funds and existing credit facilities. Completion of the Offer is conditional upon the Offer and the acquisition of Swedencare receiving all necessary regulatory, governmental or similar clearances, approvals and decisions, including approvals and clearances, competition authorities and Swedencare's board approval. The acceptance period for the Offer commences on June 21, 2023 and expires on July 26, 2023. Skandinaviska Enskilda Banken AB acted as financial advisor and Advokatfirman Vinge as legal advisor to Symrise AG.お知らせ • Feb 17+ 1 more updateSwedencare AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 final results on Apr 06, 2023お知らせ • Feb 16+ 1 more updateSwedencare AB (publ) to Report First Half, 2023 Results on Jul 27, 2023Swedencare AB (publ) announced that they will report first half, 2023 results on Jul 27, 2023お知らせ • Feb 11Swedencare AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 SWDC.Fが配当金を支払っている期間は 10 年未満です。増加する配当: SWDC.Fの配当金は増加していますが、同社は6年間しか配当金を支払っていません。配当利回り対市場Swedencare 配当利回り対市場SWDC.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SWDC.F)1.0%市場下位25% (US)1.4%市場トップ25% (US)4.1%業界平均 (Pharmaceuticals)2.0%アナリスト予想 (SWDC.F) (最長3年)3.6%注目すべき配当: SWDC.Fの配当金 ( 1.01% ) はUS市場の配当金支払者の下位 25% ( 1.38% ) と比べると目立ったものではありません。高配当: SWDC.Fの配当金 ( 1.01% ) はUS市場の配当金支払者の上位 25% ( 4.14% ) と比較すると低いです。株主への利益配当収益カバレッジ: SWDC.Fは高い 配当性向 ( 90.8% ) のため、配当金の支払いは利益によって十分にカバーされていません。株主配当金キャッシュフローカバレッジ: SWDC.Fは低い 現金配当性向 ( 18.3% ) であるため、配当金の支払いはキャッシュフローによって十分にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/14 17:56終値2026/06/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Swedencare AB (publ) 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Johan BrownABG Sundal Collier SponsoredAdela DashianJefferies LLCAdrian ElmlundNordea Markets1 その他のアナリストを表示
お知らせ • Mar 25Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.2800 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.
お知らせ • Feb 13Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.3500 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.
お知らせ • Apr 23Swedencare AB (Publ) Approves Board ChangesSwedencare AB (publ) at its Annual General Meeting held on April 23, 2026, elected Diego Maurizio and Thomas Thomsen as board members. The Annual General Meeting decided to new elect Thomas Eklund as Chairman of the Board.
お知らせ • Mar 26Swedencare Showcases Proden Plaqueoff Crunchy Dental Bites At Global Pet ExpoSwedencare was at Global Pet Expo in Orlando, Florida, from March 25 to 27 in booth #4401 showcasing ProDen PlaqueOff Crunchy Dental Bites. These bite-sized supplements help reduce plaque and tartar buildup while keeping breath fresh, all in a tasty, pet-approved format. Formulated with the brand's signature A.N ProDen (a 100% organic kelp sustainably harvested from pristine Scandinavian waters), these bites offer a simple and tasty way to support a healthier smile. ProDen PlaqueOff is formulated to work naturally without the need for chewing or brushing, supporting the prevention of plaque buildup and the softening of tartar. With no artificial additives, preservatives or flavors, pet parents can confidently give their pets a cleaner, healthier mouth without any unnecessary fillers. These supplements come in a tasty veggie flavor and are available in three convenient sizes: a six-ounce bag for medium and large dogs, a three-ounce bag for small dogs, and a three-ounce bag for cats. Easy to incorporate into any routine, these low-calorie bites can be given daily alongside a pet's regular dental care regimen. Plus, the dog formula is VOHC-approved for both plaque and tartar control, providing pet parents with a trusted, research-backed solution for long-term oral health.
お知らせ • Mar 25Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.2800 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.
お知らせ • Feb 13Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.3500 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.
お知らせ • Dec 10+ 2 more updatesSwedencare AB (publ) to Report Q2, 2026 Results on Jul 22, 2026Swedencare AB (publ) announced that they will report Q2, 2026 results on Jul 22, 2026
お知らせ • Nov 09Swedencare AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Apr 02, 2026
お知らせ • Oct 31Swedencare AB (publ), Annual General Meeting, Feb 26, 2026Swedencare AB (publ), Annual General Meeting, Feb 26, 2026.
お知らせ • May 17Swedencare AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Swedencare AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Apr 24+ 1 more updateSwedencare AB (Publ) Approves Election of Isabelle Guiller as DirectorSwedencare AB (publ) announced that at its AGM held on April 25, 2025, shareholders approved the election of Isabelle Guiller as director.
お知らせ • Mar 24Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million.Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million on March 24, 2025. Under the terms of agreement, the initial purchase price is £30 million (approximately SEK 395.4 million) along with a two-year earn-out arrangement. The cash consideration will include £27 million (approximately SEK 355.9 million) drawn from available cash and RCF-credit) and an issue-in-kind of 978,119 shares in Swedencare (approximately SEK 39.5 million) to the seller upon closing, which is expected to take place on April 1, 2025. A condition-based purchase price (earn-out) of a maximum GBP 15 million (SEK 197.7 million) may be paid if certain conditions are met as of April 1, 2027. For the calendar year 2024, Summit Veterinary Pharmaceuticals Limited had revenue of £2.7 million. Post completion of the acquiistion, Summit will continue to be led by Steve Organ, the founder and former owner, for the next two years. Steve will also become a shareholder of Swedencare with 978,119 shares. Advokatfirman Lindahl KB, with the assistance of Reynolds Porter Chamberlain LLP (RPC) acted as legal advisor to Swedencare. Lincoln International acted as exclusive financial advisor to Summit UK for the transaction. Redfern acted as exclusive legal advisor to Summit UK for the transaction. Swedencare AB (publ) (OM:SECARE) completed the acquisition of Summit Veterinary Pharmaceuticals Limited on March 24, 2025.
お知らせ • Mar 22Swedencare AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Feb 12, 2026
お知らせ • Mar 13Swedencare AB (publ) to Report Fiscal Year 2024 Results on Apr 03, 2025Swedencare AB (publ) announced that they will report fiscal year 2024 results on Apr 03, 2025
お知らせ • Jan 22Swedencare AB (publ) to Report Q3, 2025 Results on Oct 22, 2025Swedencare AB (publ) announced that they will report Q3, 2025 results on Oct 22, 2025
お知らせ • Nov 20Swedencare AB (publ) to Report Q4, 2024 Results on Mar 11, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results at 9:00 AM, Central European Standard Time on Mar 11, 2025
お知らせ • Nov 15Swedencare AB (publ), Annual General Meeting, Apr 24, 2025Swedencare AB (publ), Annual General Meeting, Apr 24, 2025.
お知らせ • Aug 23+ 1 more updateSwedencare AB (publ) to Report Q2, 2025 Results on Jul 24, 2025Swedencare AB (publ) announced that they will report Q2, 2025 results on Jul 24, 2025
お知らせ • Apr 26+ 2 more updatesSwedencare AB (publ) to Report Q4, 2024 Results on Feb 13, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results on Feb 13, 2025
お知らせ • Nov 17Swedencare AB (Publ) Announces Nomination Committee AppointmentsSwedencare AB (publ) appointed a nomination committee for the Annual General Meeting on April 25th, 2024. The Nomination Committee consists of the following persons: Håkan Svanberg, appointed by Håkan Svanberg & Co Health Care AB, Chairman of the Nomination Committee, Heinz-Juergen Bertram, appointed by Symrise AG, Anna Magnusson, appointed by Första AP-fonden.
お知らせ • Oct 26+ 3 more updatesSwedencare AB (publ), Annual General Meeting, Apr 25, 2024Swedencare AB (publ), Annual General Meeting, Apr 25, 2024.
お知らせ • Jun 07Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billionSymrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion on June 5, 2023. Under the terms, SEK 37.50 per share in cash will be acquired for 111,112,282 shares. The consideration payable in respect of the Offer is financed in full by available funds and existing credit facilities. Completion of the Offer is conditional upon the Offer and the acquisition of Swedencare receiving all necessary regulatory, governmental or similar clearances, approvals and decisions, including approvals and clearances, competition authorities and Swedencare's board approval. The acceptance period for the Offer commences on June 21, 2023 and expires on July 26, 2023. Skandinaviska Enskilda Banken AB acted as financial advisor and Advokatfirman Vinge as legal advisor to Symrise AG.
お知らせ • Feb 17+ 1 more updateSwedencare AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 final results on Apr 06, 2023
お知らせ • Feb 16+ 1 more updateSwedencare AB (publ) to Report First Half, 2023 Results on Jul 27, 2023Swedencare AB (publ) announced that they will report first half, 2023 results on Jul 27, 2023
お知らせ • Feb 11Swedencare AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023